Clinical Trial VICCHEM1323


A Phase II Randomized, Multicenter Study of Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients Who Achieve and Sustain MR4.5 After Switching to Nilotinib

Principal Investigator(s)

Sanjay Mohan


  • Protocol No. VICCHEM1323
  • Open Date: 10/03/2013
  • Staging: Phase II
  • Age Group: Adults
  • Scope: National
  • Objective: To evaluate molecular relapse free rates 6 months after discontinuation from nilotinib therapy in patients with MR4.5
  • Disease Sites: Leukemia
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: AMN107; Nilotinib
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01698905
  • Secondary Protocol No: CAMN107AUS37



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.